For research use only. Not for therapeutic Use.
Fmoc-MMAF-OMe(CAT: I040439) is a protected derivative of monomethyl auristatin F (MMAF), a potent tubulin polymerization inhibitor widely used as the cytotoxic payload in antibody-drug conjugates (ADCs). Featuring an Fmoc (9-fluorenylmethyloxycarbonyl) protecting group and methyl ester functionality, Fmoc-MMAF-OMe is ideal for peptide synthesis and linker-payload conjugation strategies in ADC development. The active core, MMAF, disrupts microtubule dynamics, leading to mitotic arrest and cell death in rapidly dividing cancer cells. Fmoc-MMAF-OMe enables precise payload incorporation and is well-suited for preclinical research, ADC design, and the development of targeted therapies for hematologic and solid tumors. Suitable for use in cytotoxic payload engineering.
CAS Number | 863971-38-4 |
Synonyms | methyl (2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoate |
Molecular Formula | C55H77N5O10 |
Purity | ≥95% |
IUPAC Name | methyl (2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoate |
InChI | InChI=1S/C55H77N5O10/c1-13-35(6)49(45(67-10)31-46(61)60-29-21-28-44(60)50(68-11)36(7)51(62)56-43(54(65)69-12)30-37-22-15-14-16-23-37)58(8)53(64)47(33(2)3)57-52(63)48(34(4)5)59(9)55(66)70-32-42-40-26-19-17-24-38(40)39-25-18-20-27-41(39)42/h14-20,22-27,33-36,42-45,47-50H,13,21,28-32H2,1-12H3,(H,56,62)(H,57,63)/t35-,36+,43-,44-,45+,47-,48-,49-,50+/m0/s1 |
InChIKey | MDJMZQUALDTONI-OVPIWJPHSA-N |
SMILES | CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(CC2=CC=CC=C2)C(=O)OC)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)OCC3C4=CC=CC=C4C5=CC=CC=C35 |
Reference | [1]. Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70. [Content Brief] |
Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |